Zevra Therapeutics, Inc. Increase (Decrease) in Accounts and Other Receivables
Zevra Therapeutics, Inc. (ZVRA) reported Increase (Decrease) in Accounts and Other Receivables of -$1.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2026-08-05
- Zevra Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-06-30 was $5.74M, a 18.08% increase year-over-year.
- Zevra Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-03-31 was -$6.89M, a 426.85% decline year-over-year.
- Zevra Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-12-31 was $6.37M, a 134.17% increase year-over-year.
- Zevra Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-09-30 was -$1.36M.
- Zevra Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2025 was $11.98M.
- Zevra Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2024 was -$6.87M, a 175.66% decline from fiscal 2023.
- Zevra Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2023 was $9.08M, a 34.05% increase from fiscal 2022.
- Zevra Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2022 was $6.77M.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.15M 10-Q · filed 2026-08-05 | $5.22M derived: sum of 3 quarters · filed 2026-08-05 | $3.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$6.89M 10-Q · filed 2026-05-06 | -$523.00K derived: sum of 2 quarters · filed 2026-05-06 | -$1.88M derived: sum of 3 quarters · filed 2026-05-06 | $2.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $5.01M derived: sum of 2 quarters · filed 2026-03-09 | $9.87M derived: sum of 3 quarters · filed 2026-08-05 | $11.98M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.50M derived: sum of 2 quarters · filed 2026-08-05 | $5.61M 10-Q · filed 2025-11-05 | $8.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $6.97M 10-Q · filed 2026-08-05 | $9.69M derived: sum of 3 quarters · filed 2026-08-05 | $8.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.11M 10-Q · filed 2026-05-06 | $4.83M derived: sum of 2 quarters · filed 2026-05-06 | $3.67M derived: sum of 3 quarters · filed 2026-05-06 | $4.31M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.56M derived: sum of 2 quarters · filed 2026-03-09 | $2.20M derived: sum of 3 quarters · filed 2026-03-09 | -$6.87M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$515.00K derived: sum of 2 quarters · filed 2025-11-05 | -$9.59M 10-Q · filed 2025-11-05 | -$2.14M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $642.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$8.43M 10-Q · filed 2025-08-12 | -$980.00K derived: sum of 3 quarters · filed 2025-08-12 | -$5.09M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$9.07M 10-Q · filed 2025-05-13 | -$1.62M derived: sum of 2 quarters · filed 2025-05-13 | -$5.73M derived: sum of 3 quarters · filed 2025-05-13 | $483.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $7.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $3.34M derived: sum of 2 quarters · filed 2025-03-12 | $9.55M derived: sum of 3 quarters · filed 2025-03-12 | $9.08M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$4.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.10M derived: sum of 2 quarters · filed 2024-11-13 | $1.63M 10-Q · filed 2024-11-13 | $3.75M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $6.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $5.73M 10-Q · filed 2024-08-14 | $7.86M derived: sum of 3 quarters · filed 2024-08-14 | $11.21M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$477.00K 10-Q · filed 2024-05-09 | $1.65M derived: sum of 2 quarters · filed 2024-05-09 | $5.00M derived: sum of 3 quarters · filed 2024-05-09 | $4.50M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $5.48M derived: sum of 2 quarters · filed 2024-04-01 | $4.98M derived: sum of 3 quarters · filed 2024-04-01 | $6.77M 10-K · filed 2024-04-01 |
| 2022-09-30 | $3.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.85M derived: sum of 2 quarters · filed 2023-11-07 | $4.65M 10-Q · filed 2023-11-07 | $4.55M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.29M 10-Q · filed 2023-08-14 | $1.20M derived: sum of 3 quarters · filed 2023-08-14 | $932.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.79M 10-Q · filed 2023-05-15 | $1.70M derived: sum of 2 quarters · filed 2023-05-15 | $1.43M derived: sum of 3 quarters · filed 2023-05-15 | -$7.99M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$360.00K derived: sum of 2 quarters · filed 2023-03-07 | -$9.78M derived: sum of 3 quarters · filed 2023-03-07 | -$1.05M 10-K · filed 2023-03-07 |
| 2021-09-30 | -$269.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$9.69M derived: sum of 2 quarters · filed 2022-11-10 | -$960.00K 10-Q · filed 2022-11-10 | -$583.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$9.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$691.00K 10-Q · filed 2022-08-12 | -$314.00K derived: sum of 3 quarters · filed 2022-08-12 | -$205.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $8.73M 10-Q · filed 2022-05-12 | $9.11M derived: sum of 2 quarters · filed 2022-05-12 | $9.21M derived: sum of 3 quarters · filed 2022-05-12 | $9.04M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $486.00K derived: sum of 2 quarters · filed 2022-03-31 | $314.00K derived: sum of 3 quarters · filed 2022-03-31 | $714.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$63.00K derived: sum of 2 quarters · filed 2021-11-10 | $337.00K 10-Q · filed 2021-11-10 | $564.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $228.00K 10-Q · filed 2021-08-13 | $455.00K derived: sum of 3 quarters · filed 2021-08-13 | $1.92M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $400.00K 10-Q · filed 2021-05-14 | $627.00K derived: sum of 2 quarters · filed 2021-05-14 | $2.09M derived: sum of 3 quarters · filed 2021-05-14 | $2.10M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $1.69M derived: sum of 2 quarters · filed 2021-03-12 | $1.71M derived: sum of 3 quarters · filed 2021-03-12 | $1.73M 10-K · filed 2021-03-12 |
| 2019-09-30 | $1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $1.48M derived: sum of 2 quarters · filed 2020-10-30 | $1.50M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $33.00K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $20.00K 10-Q · filed 2020-05-13 | |||
| 2018-09-30 | $86.00K 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |